Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012
Spectra Intelligence
November 1, 2005 91 Pages - SKU: SPIN1666315
|
|
Countries covered: United States, Global
Examines the global mood disorder sector and highlights the converging market stimulators and inhibitors that may lead to a market decline from an estimated US$17.4 billion in 2005 to US$15 billion in 2012. Key factors discussed include patent expirations of leading antidepressants over the next 7 years, increased generic substitution trends, safety concerns over SSRIs; cost-containment in prescribing; and litigation activities between research-based and generic companies. Key market stimulators identified to buffer the decline include the introduction of new drug classes, new formulations, line extensions, increased patient populations, and treatment resistance. The report also evaluates the emerging market sector of cognitive and memory impairment and shows the extent of R&D activities within the field. Analysis of both sectors reveals candidates that have top-line earning prospects and also provides an insight into potential licensing or acquisition opportunities in promising psychopharmacotherapy market subsectors.
REPORT HIGHLIGHTS AND KEY FINDINGS
- Pharmacotherapies indicated for mood disorders account for a
market valued at US$17.4 billion, which is forecast to decrease
13.6% CAGR to US$15 billion by 2012
- Critical analysis of depression, anxiety disorders, and cognitive and
memory impairment
- Review of epidemiological, aetiological, and therapeutic data for
key therapy areas
- Analysis of 10 marketed products and inclusion of 88 R&D
candidates identified in preclinical to clinical stages of
development for depressive illnesses and cognitive impairment
- Sales estimates (US$) to 2012 for major therapy areas
- Strategic insights for life-cycle optimization and product
development
- Critical evaluation of leading antidepressants
- Emerging markets identified and sector analysis
- Trend analysis of industry events and activities over past 2 years
- Detailed R&D themes and clusters by therapy area
- Data generation on sector and market values between 2004 and
2012 and therapy forecasts by 2020 (US$)
- High revenue-yielding prospects identified with projected sales
estimations
- R&D pipeline positioning for key therapy areas
- Market insights for product development and drug promotion
REASONS TO PURCHASE THIS REPORT
- Detailed survey and analysis of the current and future mood disorder market
- Comprehensive update on key marketed products indicated for depression and anxiety
disorders
- Review of epidemiological, demographic, aetiological, and therapeutic data associated with
mood disorders and cognitive impairment
- Market analysis and insight of key therapy areas and pipelines
- Market value predictions of individual marketed products to 2012
- Insight and trend analysis of pipeline products for depressive illnesses and cognitive and
memory impairment
- Review of promising pipeline products and potential market opportunities
- Insight into potential blockbusters in the mood disorder and cognitive impairment therapy
areas
- Illustrates unmet needs of current pharmacotherapies to treat mood disorders and the
underserved area of cognitive impairment
- Provides extensive coverage of the R&D pipeline of key players in the depression/anxiety
disorders and cognitive/memory impairments
- Illustrates potential high-revenue earning prospects that are differentiated by novel indications
or mechanism of action
- Provides leads for potential licensing opportunities
|
Additional InformationCOMPANIES MENTIONED IN REPORT
- ABIOGEN,
- ABRIKA PHARMACEUTICALS,
- ALPHAPHARM,
- ALPHARMA,
- AMARIN,
- ANCHEN PHARMACEUTICALS,
- ANTARES PHARMA,
- APOTEX,
- ASTRAZENECA,
- BARR LABORATORIES,
- BENTLEY PHARMACEUTICALS,
- BIOVAIL,
- BOEHRINGER INGELHEIM,
- BRISTOL-MYERS SQUIBB,
- BTG,
- CARACO PHARMACEUTICAL,
- LABORATORIES,
- CEPHALON,
- CIMA LABS,
- CIPLA,
- COLLEGIUM PHARMACEUTICALS,
- CORTEX PHARMACEUTICALS,
- CYPRESS BIOSCIENCE,
- DOV,
- DR REDDY’S LABORATORIES,
- EON LABS,
- ENHANCE BIOTECH,
- FABRE-KRAMER PHARMACEUTICALS,
- FOREST LABORATORIES,
- GENAISSANCE PHARMACEUTICALS,
- GLAXOSMITHKLINE,
- HELICON THERAPEUTICS,
- HEXAL,
- IMPAX LABORATORIES,
- IPSEN,
- IVAX,
- JOHNSON & JOHNSON,
- LILLY,
- MERCK,
- MEMORY PHARMACEUTICALS,
- MYLAN LABORATORIES,
- NEUROCRINE,
- NEUROGEN,
- NEUROSEARCH,
- NEURO3D,
- NOVARTIS,
- ONO PHARMACEUTICALS,
- ORGANON,
- PENTECH PHARMACEUTICALS,
- PFIZER,
- PHARMACEUTICAL RESOURCES,
- PHARMOS,
- PHERIN PHARMACEUTICALS,
- PREDIX,
- PRESCIENT NEURO-PHARMA,
- ROCHE,
- SAEGIS PHARMACEUTICALS,
- SEPRACOR,
- SHIONOGI,
- SPECTRUM PHARMACEUTICALS,
- SYNTHON PHARMACEUTICALS,
- SANOFI-AVENTIS,
- SENTION PHARMA,
- SERVIER,
- SK PHARMA,
- SKYEPHARMA,
- SOLVAY PHARMACEUTICALS,
- SOMERSET PHARMACEUTICALS,
- TAISHO,
- TARGACEPT,
- TETRAGENEX,
- TEVA PHARMACEUTICAL,
- TORPHARM,
- LUNDBECK,
- UCB PHARMA,
- VANDA PHARMACEUTICALS,
- VELA PHARMACEUTICALS,
- WATSON PHARMACEUTICALS,
- WYETH
- List of Tables
- List of Figures
- Executive Summary
- Objectives of the Report
- Research Methodology
- Chapter 1 Introduction to Mood Disorders and Cognitive Impairment
- Depression
- Prevalence
- Aetiology of Depression
- Types of Depression
- Major depression
- Dysthymia
- Bipolar Disorder
- Symptoms of Depression
- Anxiety Disorders
- Prevalence
- Cognitive Impairments and Memory Deficits
- Prevalence
- Pharmacotherapy for Cognitive Impairment
- Chapter 2 The Global Market for Mood Disorders: Depression and Anxiety
- Mood Disorders: Depression and Anxiety
- Market Overview of Drugs to Treat Depression and Anxiety Disorders
- Market Analysis and Insights for Drugs to Treat Depressive Illnesses
- Market Analysis: Antidepressant Therapy Area
- Prozac (Fluoxetine) - Eli Lilly
- Product Overview
- Indications and Supplementary Labelling
- Patent Expiry and Reformulation
- Sales Prospects
- Commercial Outlook
- Cymbalta (Duloxetine) - Eli Lilly/Boehringer Ingelheim
- Product Overview
- Indications and Supplementary Labelling
- Sales Prospects
- Commercial Outlook
- Zoloft/Lustral (Sertraline) - Pfizer
- Product Overview
- Indications and Supplementary Labelling
- Patent Expiry and Reformulation
- Sales Prospects
- Commercial Outlook
- Seroxat/Paxil/Deroxat (Paroxetine) - GlaxoSmithKline
- Product Overview
- Indications and Supplementary Labelling
- Patent Expiry and Reformulation
- Sales Prospects
- Commercial Outlook
- Wellbutrin (Bupropion) - GlaxoSmithKline
- Product Overview
- Indications and Supplementary Labelling
- Patent Expiry and Reformulation
- Sales Prospects
- Commercial Outlook
- Effexor (Venlafaxine) - Wyeth
- Product Overview
- Indications and Supplementary Labelling
- Patent Expiry and Reformulation
- Sales Prospects
- Commercial Outlook
- Remeron/Zispin (Mirtazapine) - Organon/Akzo Nobel
- Product Overview
- Indications and Supplementary Labelling
- Patent Expiry and Reformulation
- Sales Prospects
- Commercial Outlook
- Cipramil/Celexa (Citalopram) - Lundbeck/Forest Laboratories
- Product Overview
- Indications and Supplementary Labelling
- Patent Expiry and Reformulation
- Sales Prospects
- Commercial Outlook
- Cipralex/Lexapro (Escitalopram) - Lundbeck/Forest
- Product Overview
- Indications and Supplementary Labelling
- Patent Expiry and Reformulation
- Sales Prospects
- Commercial Outlook
- Future Considerations and Market Insights for the Antidepressant Market
- Pipeline Antidepressants
- Pipeline Focus
- Valdoxan (Agomelatine) - Servier
- Pharmacotherapeutics for Cognitive Impairment and /Memory Deficits
- Future Market Focus - Age-Related Cognitive Decline
- Nootropil (Piracetam) - UCB Pharma
- Companies Developing Drugs for Cognitive and Memory Impairment
- EGb 761/Tanakan - Ipsen
- Chapter 3 Drugs in Research and Development
- Pipeline Mood Stabilizers and Drugs for Cognitive Impairment
- Drugs in Development for Mood Disorders: Antidepressants and Anxiolytics
- Depression and Anxiety: Research and Development Overview
- Drugs in Development for Cognitive and Memory Impairment
- Cognitive/Memory Impairment - Research and Development Overview
- Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining
- Data Analysis, Therapy Forecasting, and Prospect Mining
- Market Analysis and Therapy Forecasting
- Antidepressants and Anxiolytics
- Therapy Area Forecasts
- Comparative Analysis: Antidepressant/Anxiolytic Product Sales
- Prospect Mining
- Mood Disorders: Depression and Anxiety
- Cognitive and Memory Impairment
- Therapy Area Forecasts, 2012 and 2020
- Chapter 5 Report Synopsis
- Depressive/Anxiety and Cognitive/Memory Impairment - Key Data Points
- Bibliography and Reference Sources
- List of Tables
- Table 1.1 Role of Neurotransmitters in Depression
- Table 1.2 Symptoms of Depression and Bipolar Disorder/Mania
- Table 1.3 Major Anxiety Disorders
- Table 1.4 Causes of Dementia
- Table 2.1 Estimated Global Sales & Forecasts of Leading Antidepressants, 2004-2012 (US$m)
- Table 2.2 Estimated Annual Growth Rates of Leading Antidepressants (%), 2004-2012
- Table 2.3 Leading Antidepressants Ranked by Sales, 2005 & 2012
- Table 2.4 Primary and Secondary Indications for Antidepressants
- Table 2.5 Estimated Sales (US$) and Annual Growth (%) of Prozac, 2005-2012
- Table 2.6 Estimated Sales (US$) and Annual Growth (%) of Cymbalta, 2005-2012
- Table 2.7 Estimated Sales (US$) and Annual Growth (%) of Zoloft, 2005-2012
- Table 2.8 Estimated Sales (US$) and Annual Growth (%) of Seroxat/Paxil, 2005-2012
- Table 2.9 Estimated Sales (US$) and Annual Growth (%) of Wellbutrin, 2005-2012
- Table 2.10 Estimated Sales (US$) and Annual Growth (%) of Effexor, 2005-2012
- Table 2.11 Estimated Sales (US$) and Annual Growth (%) of Remeron, 2005-2012
- Table 2.12 Estimated Sales (US$) and Annual Growth (%) of Cipramil/Celexa, 2005-12
- Table 2.13 Estimated Sales (US$) and Annual Growth (%) of Cipralex/Lexapro, 2005-12
- Table 2.14 Drugs in Development for Cognitive and Memory Impairment, 2005 (partial)
- Table 3.1 Drugs in Development for Depression and Anxiety, 2005
- Table 3.2 Drugs in Development for Cognitive and Memory Impairment, 2005
- Table 4.1 Global Drug Market for Antidepressants and Anxiolytics (US$m) 2004-2012
- Table 4.2 Therapy Area Forecasts for the Global Mood Disorders and Cognitive Impairment Market Sectors, 2012 and 2020
- List of Figures
- Figure 2.1 Estimated Global Sales of Leading Antidepressants, 2005 & 2012
- Figure 2.2 Estimated Market Share of Leading Antidepressants, 2005 & 2012
- Figure 4.1 Therapy Area Forecasts for Antidepressants and Anxiolytics, 2005 & 2012 (US$m)
- Figure 4.2 Comparative Analysis of Leading Antidepressants and Anxiolytics 2004-2012
- Figure 4.3 Key Antidepressant/Anxiolytic Prospects in the CNS Development Pipeline, 2005
- Figure 4.4 Key Cognitive and Memory Impairment Prospects in the CNS Development Pipeline, 2005
More Global Behavioral Health Reports
Anxiety Disorders by
Global Industry Analysts
This report analyzes the worldwide markets for Anxiety Disorders in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest ...
Bipolar Depression Global Clinical Trials Review, Q4, 2010 by
GlobalData
Bipolar Depression Global Clinical Trials Review, Q4, 2010 Summary GlobalData's clinical trial report, “Bipolar Depression Global Global Clinical Trials Review, Q4, 2010""” provides ...
Disease and Therapy Review: Major Depressive Disorder by
Timely Data Resources, Inc.
The Major Depressive Disorder Disease and Therapy Review provides an overview of the disease and related conditions, with prevalence numbers and percentages for major countries ...
Bipolar Disorder by
Global Industry Analysts
This report analyzes the worldwide markets for Bipolar Disorder in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific and Rest ...
ADHD Therapeutics by
Global Industry Analysts
This report analyzes the worldwide markets for ADHD Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US and Rest of ...
See all reports like this >>
Share this report
Other tasks Related Markets Behavioral Health Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
